FOXM1 and ovarian carcinoma: Our results clearly showed that domatinostat inhibited the expression of FOXM1 in ovarian cancer cells at clinically relevant concentrations and accordingly reduced their viability and enhanced the growth inhibitory effects of standard ovarian cancer chemotherapeutic agents cisplatin and paclitaxel.